Table 3.

Volume and MD for ROIs in controls, patients and the separate disease groups.

Measure	Hemisphere	Controls	All patients	Rheumatic disease	Nephrotic syndrome
Hippocampal volume	Right	2352 ± 276	2186 ± 196	2188 ± 212	2182 ± 176
	Left	2265 ± 300	2181 ± 217	2178 ± 204	2214 ± 245
Hippocampal MD	Right	903 ± 16	892 ± 18	893 ± 13	890 ± 24
	Left	877 ± 17	872 ± 22	873 ± 22	870 ± 22
Amygdala volume	Right	1234 ± 113	1193 ± 128	1190 ± 127	1198 ± 135
	Left	1197 ± 110	1162 ± 109	1154 ± 115	1177 ± 101
Amygdala MD	Right	839 ± 21	838 ± 16	837 ± 15	840 ± 17
	Left	827 ± 23	821 ± 20	819 ± 21	823 ± 19
Putamen volume	Bilateral	8721 ± 808	8156 ± 695	8053 ± 607	8305 ± 814
Putamen MD		797 ± 13	793 ± 16	778 ± 16	801 ± 14
Caudate nucleus volume	Bilateral	7637 ± 920	7404 ± 844	7282 ± 684	7582 ± 1045
Caudate nucleus MD		798 ± 22	793 ± 19	786 ± 16	802 ± 20
Accumbens volume	Bilateral	505 ± 61	493 ± 58	490 ± 47	498 ± 74
Accumbens MD		835 ± 20	831 ± 30	810 ± 32	837 ± 27
Total brain volume (cm3)	NA	1264 ± 108	1201 ± 104	1185 ± 112	1230 ± 88
Whole brain MD	NA	800 ± 16	796 ± 14	792 ± 11	801 ± 15

MD: mean diffusivity. Values are mean ± standard deviation. Volumes are given as mm³ if not stated otherwise and MD is given as 10⁻⁶ m²/s. Volume measures included 30 controls, 19 patients with rheumatic disease, and 11 with nephrotic syndrome. MD measures included 28 controls, 16 patients with rheumatic disease, and 11 with nephrotic syndrome.